Skip to main content

Table 1 In vitro activity of BMAP-27, BMAP-28, P19(9/B), and Tobramycin against P. aeruginosa, S. maltophilia and S. aureus CF strains

From: Potential novel therapeutic strategies in cystic fibrosis: antimicrobial and anti-biofilm activity of natural and designed α-helical peptides against Staphylococcus aureus, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia

Bacterial strains (n) Test agent:
BMAP-27 BMAP-28 P19(9/B) TOBRAMYCIN
P. aeruginosa (25)
MIC50a 8 16 8 16
MIC90b 16 32 32 >64
MICrange 4-16 4–32 4–32 2- > 64
MBC50c 8 16 16 32
MBC90d 16 32 64 >64
MBCrange 4–16 4–64 4- > 64 2- > 64
MBC/MIC 1.3 1.2 1.9e 1.5f
S. maltophilia (27)
MIC50a 4 4 4 >64
MIC90b 8 4 16 >64
MICrange 4-8 2–8 4–32 4- > 64
MBC50c 8 4 8 >64
MBC90d 16 8 32 >64
MBCrange 4–32 2–16 4–64 8- > 64
MBC/MIC 1.9 1.3 1.7 1.3g
S. aureus (15)
MIC50a 64 8 64 >64
MIC90b >64 32 >64 >64
MICrange 32- > 64 4–32 32- > 64 4- > 64
MBC50c >64 8 >64 >64
MBC90d >64 32 >64 >64
MBCrange 64- > 64 4–32 32- > 64 4- > 64
MBC/MIC 1.2h 1.2 1.2i 1.0l
Total (67)
MIC50a 8 4 8 >64
MIC90b >64 16 64 >64
MICrange 4->64 2–32 4- > 64 2- > 64
MBC50c 8 8 16 >64
MBC90d >64 16 >64 >64
MBCrange 4- > 64 2–64 4- > 64 2- > 64
MBC/MIC 1.5m 1.2 1.7n 1.4o
  1. a, bMIC50 and MIC90: MIC (μg/ml) inhibiting 50 and 90% of the strains tested, respectively.
  2. c, d MBC50 and MBC90: MBC (μg/ml) eradicating 50 and 90% of the strains tested, respectively.
  3. Only isolates exhibiting in range MIC values were considered for killing quotient calculation (MBC/MIC): en = 24; fn = 12; gn = 3; hn = 6; in = 2; mn = 58; nn = 57;on = 17.